Dr. Lewis Cantley Awarded Johnson & Johnson Dr. Paul Janssen Award for Biomedical Research
Johnson & Johnson Celebrates Role of Scientists In Society with 2020 Dr. Paul Janssen Award for Biomedical Research, Part of the Champions of Science® Initiative. Lewis Cantley, Ph.D. Named 2020 Award Winner for the Discovery of PI3K Enzyme and its Role in Wide Range of Diseases from Diabetes to Cancer
NEW BRUNSWICK, NJ – August 20, 2020 – Johnson & Johnson today announced Lewis Cantley, Ph.D., of Weill Cornell Medicine and NewYork-Presbyterian as the winner of the 2020 Dr. Paul Janssen Award for Biomedical Research for his incisive research revealing the fundamental aspects of metabolism that have profound implications for the understanding, diagnosis and treatment of human diseases such as cancer and diabetes.
“Like all of the past Dr. Paul Janssen Award winners, and indeed like Dr. Janssen himself, Dr. Cantley challenged the status quo, asked provocative questions, and tirelessly followed his curiosity to uncover scientific insights that have led to an expanded understanding of human biology and the development of solutions that can improve people’s lives,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson. “We are proud to honor the legacy of Dr. Janssen by celebrating today's research pioneers like Dr. Cantley.”
Selected by an independent committee of world-renowned scientists, Cantley won for his discovery of phosphoinositide 3 kinase (PI3K), a key enzyme that promotes cell growth and division, and plays a critical role in diseases including cancer to diabetes, as well as rare diseases such as mosaicism. He joins 18 scientists who have received the Dr. Paul Janssen Award since 2004, including three who went on to win the Nobel Prize.
The full story can be found on the Johnson & Johnson website here.
